Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic (NYSE: MDT) launched the MiniMed Go™ Smart MDI system with the Simplera™ sensor across Europe beginning Feb 2026. The system integrates InPen™ smart insulin pen and Simplera™ CGM into one app, offering real-time dose calculation, missed-dose alerts, CareLink Clinic MDI reports, and expanded pediatric labeling.
Rollout is gradual across Europe; Instinct Go™ compatibility is pending CE mark and Simplera™ compatibility in the U.S. is under FDA review.
MiniMed Group (proposed Nasdaq: MMED) launched its IPO roadshow on Feb 24, 2026, offering 28,000,000 shares with an expected price range of $25.00–$28.00 per share and a 30-day over-allotment option for 4,200,000 shares.
Upon completion Medtronic (NYSE: MDT) would retain approximately 90.03% ownership (or 88.70% if the over-allotment is exercised). Proceeds will fund general corporate purposes, repay intercompany debt, and provide additional consideration to Medtronic. A Form S-1 has been filed but is not yet effective.
Medtronic (NYSE: MDT) reported Q3 FY26 revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, with GAAP diluted EPS of $0.89 and non-GAAP diluted EPS of $1.36.
Notable drivers: Cardiac Ablation Solutions +80% (U.S. +137%), Diabetes organic +8.3%, CE Mark for Sphere-360, U.S. FDA clearances for Hugo robotic surgery and Stealth AXiS, and two M&A deals (CathWorks, Anteris). Company reiterated FY26 organic revenue ~5.5% and non-GAAP EPS guidance of $5.62–$5.66 (tariff impact ~$185M).
Medtronic (NYSE:MDT) announced that the first U.S. commercial surgical case using the FDA-cleared Hugo™ robotic-assisted surgery (RAS) system was performed at Cleveland Clinic on Feb. 17, 2026, where a robotic-assisted prostatectomy was completed and the patient discharged the next day.
The Hugo RAS system completed the Expand URO IDE study meeting primary safety and effectiveness endpoints and is available in more than 35 countries; Medtronic plans indication expansion into gynecologic and general surgery.
Medtronic (NYSE: MDT) announced FDA clearance of the Stealth AXiS™ surgical system on Feb 13, 2026, a unified platform that integrates planning, navigation and robotics for spine surgery.
The system features LiveAlign™ segmental tracking for real-time anatomic motion visualization, a modular robotic design for staged deployment, and architecture intended to support future cranial and ENT applications pending 510(k) clearance.
Medtronic (NYSE: MDT) will report third-quarter fiscal 2026 results on Tuesday, February 17, 2026, covering the quarter ended January 23, 2026.
A news release with summary financial information will be issued at ~5:45 a.m. Central Standard Time, followed by a video webcast at 7:00 a.m. CST. Replay and transcript will be posted within 24 hours.
Medtronic (NYSE:MDT) announced its intent to acquire CathWorks for up to $585 million, exercising an option tied to a 2022 strategic partnership. The acquisition aims to expand Medtronic's interventional cardiology portfolio by integrating the CathWorks FFRangio® System, an AI-driven angiography-derived coronary physiology platform.
Deal is subject to United States FTC clearance, expected by the end of Medtronic's fiscal 2026; Medtronic says the transaction is immaterial to FY2027 EPS and neutral to accretive thereafter.
Medtronic (NYSE: MDT) announced three U.S. milestones on Feb 2, 2026: Medicare access for the MiniMed 780G system paired with Abbott's Instinct sensor, FDA clearance to use ultra rapid-acting insulins (Fiasp and Lyumjev) with the 780G, and FDA clearance of the 780G with Instinct for insulin-requiring type 2 diabetes.
These actions expand sensor and insulin options, enable interoperable automated glycemic control for type 2 users, and aim to broaden access and personalization for people using automated insulin delivery.
Medtronic (NYSE:MDT) announced two milestones for the Affera Sphere-360 pulsed field ablation (PFA) catheter: CE Mark in Europe and completion of first cases in the U.S. Horizon 360 IDE pivotal trial on Jan 23, 2026. The Sphere-360 is a rotation-free, all-in-one mapping and single-shot PFA catheter that adapts to pulmonary vein anatomy, provides real-time local impedance, and integrates with the Affera mapping and ablation system. A prospective European single-arm study presented one-year data showing efficacy, safety, and durability that supported CE Mark. The Horizon 360 IDE will evaluate safety and effectiveness for treating paroxysmal atrial fibrillation in U.S. centers.
Medtronic (NYSE: MDT) announced FDA 510(k) clearance of the MiniMed Go™ app and Smart MDI system on January 12, 2026. The system links the InPen smart insulin pen with Abbott's Instinct sensor to provide real-time glucose data, dose calculations, missed-dose alerts, and CareLink reporting. Cleared for insulin-requiring type 1 and type 2 diabetes ages 7+, and ages 2–6 under caregiver supervision. Commercial launch in the U.S. is expected in spring 2026. Compatibility of Simplera sensor remains under FDA review.